Literature DB >> 35671005

Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.

Harry H Yoon1, Haidong Dong2, Qian Shi3.   

Abstract

Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments. See related article by Okada et al., p. 3277. ©2022 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35671005      PMCID： PMC9357158          DOI： 10.1158/1078-0432.CCR-22-0932

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  5 in total

1.  CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.

Authors:  Yiyi Yan; Siyu Cao; Xin Liu; Susan M Harrington; Wendy E Bindeman; Alex A Adjei; Jin Sung Jang; Jin Jen; Ying Li; Pritha Chanana; Aaron S Mansfield; Sean S Park; Svetomir N Markovic; Roxana S Dronca; Haidong Dong
Journal:  JCI Insight       Date:  2018-04-19

2.  Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).

Authors:  Morihito Okada; Ken Kato; Byoung Chul Cho; Masanobu Takahashi; Chen-Yuan Lin; Keisho Chin; Shigenori Kadowaki; Myung-Ju Ahn; Yasuo Hamamoto; Yuichiro Doki; Chueh-Chuan Yen; Yutaro Kubota; Sung-Bae Kim; Chih-Hung Hsu; Eva Holtved; Ioannis Xynos; Yasuhiro Matsumura; Akira Takazawa; Yuko Kitagawa
Journal:  Clin Cancer Res       Date:  2022-08-02       Impact factor: 13.801

3.  The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.

Authors:  Shogo Kumagai; Yosuke Togashi; Takahiro Kamada; Eri Sugiyama; Hitomi Nishinakamura; Yoshiko Takeuchi; Kochin Vitaly; Kota Itahashi; Yuka Maeda; Shigeyuki Matsui; Takuma Shibahara; Yasuho Yamashita; Takuma Irie; Ayaka Tsuge; Shota Fukuoka; Akihito Kawazoe; Hibiki Udagawa; Keisuke Kirita; Keiju Aokage; Genichiro Ishii; Takeshi Kuwata; Kenta Nakama; Masahito Kawazu; Toshihide Ueno; Naoya Yamazaki; Koichi Goto; Masahiro Tsuboi; Hiroyuki Mano; Toshihiko Doi; Kohei Shitara; Hiroyoshi Nishikawa
Journal:  Nat Immunol       Date:  2020-08-31       Impact factor: 25.606

4.  Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

Authors:  Yuichiro Doki; Jaffer A Ajani; Ken Kato; Jianming Xu; Lucjan Wyrwicz; Satoru Motoyama; Takashi Ogata; Hisato Kawakami; Chih-Hung Hsu; Antoine Adenis; Farid El Hajbi; Maria Di Bartolomeo; Maria I Braghiroli; Eva Holtved; Sandra A Ostoich; Hye R Kim; Masaki Ueno; Wasat Mansoor; Wen-Chi Yang; Tianshu Liu; John Bridgewater; Tomoki Makino; Ioannis Xynos; Xuan Liu; Ming Lei; Kaoru Kondo; Apurva Patel; Joseph Gricar; Ian Chau; Yuko Kitagawa
Journal:  N Engl J Med       Date:  2022-02-03       Impact factor: 176.079

5.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.